Emmanuel Macron is France's youngest leader since Napoleon

May 8, 2017

Paris, May 8: Three years ago, hardly anyone knew his name.

But in a once-unimaginable scenario, Emmanuel Macron - at 39, the boy wonder of an aging political establishment - won the French presidency Sunday with a tidal wave of popular support. He will soon be France's youngest head of state since Napoleon Bonaparte as well as its first modern president not to belong to either of the center-left or center-right parties that have run this country for 60 years.

emmanuel

After the success of the Brexit campaign in Britain and the upset victory of Donald Trump in the U.S. presidential election, Macron's win has been billed as having curbed the global tide of anti-establishment populism. In the vote's second and final round, he defeated Marine Le Pen, the leader of the far-right National Front, a strongly anti-immigrant party tainted by the perception that it is tolerant of anti-Semitism and Nazi nostalgia.

"I will fight with all my strength against the division that is undermining and defeating us," Macron said, just after the results were announced. "For the next five years, I will serve on your behalf with humility, devotion and determination."

Macron's story is one of a highly improbable ascent in a system that typically rewards entrenched political dynasties.

"It's entirely unprecedented in the Fifth Republic," said Francois Heisbourg, a well-known French defense expert who has advised Macron on security and terrorism issues. "It's extraordinarily unusual, the way he has broken through the system - coming from nowhere."

Macron, who has never held elected office, has now been elected to one of the most powerful executive offices in the Western world, holding the top job of the second-largest economy in a troubled Europe. How he did it, analysts say, rests on a combination of luck and a campaign message attuned to a new political moment.

In France, 2017 proved an ideal year to run as an independent candidate. A rare political vacuum emerged, and Macron - a former Socialist economy minister who stepped down from his post in July - was able to take full advantage of it.

With the public frightened by a slew of terrorist attacks by Islamist extremists, and with employment at double digits, France's Socialist Party, under incumbent President Francois Hollande, sank to historic levels of unpopularity. Largely for the sake of the party, Hollande promised in December not to seek re-election, but his Socialist stand-in, Benoit Hamon, was eliminated in the election's first round, winning just a meager 6.35 percent of the vote.

France's mainstream conservative party, Les Republicains (the Republicans), were undermined by a spending scandal involving Francois Fillon, its contender. Once the undisputed favorite, Fillon suffered a fatal blow after Le Canard Enchaine, a French satirical newspaper, accused him of funneling about 900,000 euros ($990,000) of public funds to his wife and children for work they never did.

Macron perceived that the "new divide" among French voters was not the historic cleavage between left and right but rather one between an open and closed society, Heisbourg said. This was the line Le Pen and the National Front had embraced for years, but few in the established parties ever responded directly.

Defending an open, multicultural society was a central component of En Marche (Onward), the movement Macron launched in 2016. "Globalization can be a great opportunity," he said at one point on the campaign trail. "There is no such thing as French culture," he said at another. "There is culture in France, and it is diverse."

The great French novels are often stories of ambitious young men from the provinces who come to Paris to seek their fortunes. For many, Macron is no exception. The literary son of doctors from provincial Amiens, he graduated from France's elite Ecole Normale d'Administration, the traditional breeding ground of presidents.

Some in the French press have placed the first sign of Macron's formidable ambitions in, of all places, his love life - namely, in his dogged pursuit of his wife, Brigitte, his former high school teacher and a woman 24 years his senior. As Brigitte Macron told a French documentary maker last year: "Bit by bit, he defeated all my resistance, in an amazing way, with patience." The candidate showed the same persistence in capturing the Elysee Palace.

"I have known failures, sometimes bitter, but I have never allowed myself to turn away," Macron wrote in his 2016 book, "Revolution."

That doggedness - along with a calculating eye for useful associations, critics say - brought him into contact with many prominent French thinkers and government officials, who then helped him advance.

In the late 1990s, while still a graduate student, Macron worked as an assistant to Paul Ricoeur, a prominent French intellectual and writer; by the mid-2000s, he was working for the Finance Ministry, on a commission dedicated to stimulating economic growth. It was there that he met Jacques Attali, a prominent economist and Parisian power broker who many say later ushered Macron along a speedy path to the highest echelons of the Hollande administration.

In an interview, Attali, who has also served as an adviser to the Macron campaign, rejected out of hand the idea that the candidate was mainly a gifted networker. "He would be where he is today with or without my help," Attali said.

If Macron's ambition has led him to considerable success, it has also earned him enemies - including, some say, Hollande, whom he served as economy minister but then abandoned to launch his party. "Emmanuel Macron betrayed me methodically," Hollande said last year, according to Le Monde newspaper.

Jean Pisani-Ferry, another Macron adviser and the author of much of the candidate's platform, brushed off the comment.

"He launched another politics, created a new movement. Political life wouldn't exist otherwise," Pisani-Ferry said in an interview.

Despite the improbable nature of Macron's victory, France's new president will face a considerable challenge as he attempts to form a government. Given that he has no party structure behind him, he will be deeply affected by the results of parliamentary elections, slated for June.

"There is huge uncertainty regarding the parliamentary elections to come, because France's main political forces were largely absent in the second round - the traditional right wing, the Socialists and the far left," said Patrick Weil, a leading French legal scholar and historian. "Now they are frustrated, and they are ready to take their revenge in the legislative elections."

In the past, when the National Front made it to the final round of the presidential election, the rest of the political spectrum united in opposition to the extreme right. But this year, certain politicians hesitated to back Macron in the final round, notably the far-leftist Jean-Luc Melenchon. Many voters also opted to abstain or to cast blank ballots.

"You might have higher mobilization for the parliamentary elections than usual, which, given turnout in the presidential election, could mean a higher legitimacy for the parliament than for the presidency," Weil said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 3,2020

Washington, Jun 3: US President Donald Trump's administration on Tuesday announced investigations into foreign digital services taxes it says are aimed squarely at American tech firms.

Following a similar trade investigation against France last year, the US Trade Representative office now is looking into taxes in Britain and the European Union, as well as Indonesia, Turkey and India.

"President Trump is concerned that many of our trading partners are adopting tax schemes designed to unfairly target our companies," USTR Robert Lighthizer said in a statement.

"We are prepared to take all appropriate action to defend our businesses and workers against any such discrimination."

Washington opposes the efforts to tax revenues from online sales and advertising, saying they single out US tech giants like Google, Apple, Facebook, Amazon and Netflix.

The US and France have agreed to negotiate till the end of the year over a digital services tax Paris approved in 2019, after USTR found them to be discriminating and threatened retaliatory duties of up to 100 percent on French imports such as champagne and camembert cheese.

Trump has embroiled the US in numerous trade disputes since taking office in 2017, including a months-long trade war with China that cooled with the signing of a partial deal in January.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 9,2020

Islamabad, May 9: A female doctor posted at Pakistan Institute of Medical Sciences (Pims) Mother and Child Hospital (MCH), who was tested Covid-19 positive, has exposed Pakistan's mismanagement in handling the patients affected with the deadly virus.

Identified herself as Dr. Sharbat, she made a video of herself locked in an isolated room when the authorities failed to provide any medical assistance to her.

According to Pakistani media, the Pakistan Institute of Medical Sciences (Pims) Mother and Child Hospital (MCH) and the operating theatre in the Children's Hospital were sealed on Tuesday after 15 people from both facilities were diagnosed with Covid-19.

Dr. Sharbat said that despite having Covid-19 symptoms after her colleague doctor was tested positive, she was forced to perform duty by the hospital authorities.

After she tested positive, Dr. Sharbat has isolated herself in a room and has requested the hospital authorities to provide her a bed in the hospital.

She said, "I am isolated in a small room. There is no toilet and other facilities at this place. I have requested the authorities several times to provide me proper bed because I cannot go home as my son and father is there. I have no other place to go. Its been several hours now and the administration is busy doing meetings. They have no idea about my location. I have called the concerned officials several times and requested for a room in the hospital, but they said that they are looking for it. This is the kind of arrangements we have that a doctor, who was serving the patients, is not able to get proper care".

Dr Sharbat said that she is feeling depressed after seeing the response of authorities tackling with Covid-19 crisis in the country.

She added, "It is unfortunate that the government salutes [health professionals] but is not willing to provide isolation rooms."

Pakistan's position in the global ranking in respect of Covid-19 dropped from 24th to 22nd after the number of positive cases increased to 26,806 (till May 08) with the addition of 1,791 new cases.

However, the National Coordination Committee (NCC), chaired by Prime Minister Imran Khan, had decided to substantially ease the lockdown from Saturday after detailed deliberations and consultations with the provinces.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 4,2020

Jun 4: A malaria drug President Donald Trump took to try to prevent COVID-19 proved ineffective for that in the first large, high-quality study to test it in people in close contact with someone with the disease.

Results published Wednesday by the New England Journal of Medicine show that hydroxychloroquine was no better than placebo pills at preventing illness from the coronavirus.

The drug did not seem to cause serious harm, though -- about 40% on it had side effects, mostly mild stomach problems.

 “We were disappointed. We would have liked for this to work,” said the study leader, Dr. David Boulware, an infectious disease specialist at the University of Minnesota.

“But our objective was to answer the question and to conduct a high-quality study,” because the evidence on the drug so far has been inconclusive, he said.

Hydroxychloroquine and a similar drug, chloroquine, have been the subject of much debate since Trump started promoting them in March.

Hydroxychloroquine has long been used for malaria, lupus, and rheumatoid arthritis, but no large studies have shown it or chloroquine to be safe or effective for much sicker patients with coronavirus, and some studies have suggested the drugs may do harm.

Trump took a two-week course of hydroxychloroquine, along with zinc and Vitamin D, after two staffers tested positive for COVID-19, and had no ill effects, according to results of his latest physical released by his doctor Wednesday.

Federal regulators have warned against hydroxychloroquine's use except in hospitals and formal studies because of the risk of side effects, especially heart rhythm problems.

Boulware's study involved 821 people in the United States and Canada living with someone diagnosed with COVID-19 or at high risk of getting it because of their job -- doctors, nurses, ambulance workers who had significant exposure to a sick patient while not wearing full protective gear.

They were randomly assigned to get either the nutrient folate as a placebo or hydroxychloroquine for five days, starting within four days of their exposure. Neither they nor others involved in the research knew who was getting which pills.

After 14 days in the study, 12 per cent on the drug developed COVID-19 symptoms versus 14 per cent in the placebo group, but the difference is so small it could have occurred by chance, Boulware said.

“There's basically no effect. It does not prevent infection,” he said of the drug. Even if it were to give some slim advantage, “we'd want a much larger effect” to justify its use and risk of side effects for preventing illness, he said.

Results were no different among a subgroup of participants who were taking zinc or vitamin C, which some people believe might help make hydroxychloroquine more effective or fight the coronavirus.

There are some big caveats: The study enrolled people through the Internet and social media, relying on them to report their own symptoms rather than having them tracked in a formal way by doctors.

Participants were not all tested for the coronavirus but were diagnosed as COVID-19 cases based on symptoms in many cases. And not all took their medicines as directed.

The results “are more provocative than definitive,” and the drug may yet have prevention benefits if tried sooner or in a different way, Dr. Myron Cohen of the University of North Carolina at Chapel Hill wrote in a commentary in the journal.

Others were glad to see a study that had a comparison group and good scientific methods after so many weaker reports on hydroxychloroquine.

“This fits with everything else we've seen so far which suggests that it's not beneficial," said Dr. Peter Bach, director of a health policy center at Memorial Sloan Kettering Cancer Center in New York.

This study was in younger relatively healthy people, but the results “would make me very discouraged about trying to use this in older people” who are most vulnerable to serious illness from the coronavirus, Bach said.

“If it does work, it doesn't work very well.” Dr. Dan Culver, a lung specialist at the Cleveland Clinic, said there's still a chance that giving the drug sooner than four days after someone's exposure to the virus may help prevent illness.

But the study “takes 'home run' off the table” as far as hopes for the drug, he said.

The study was mostly funded by David Baszucki, founder of Roblox, a California-based game software company, and other private donors and the Minnesota university.

Boulware also is leading a study testing hydroxychloroquine for treating COVID-19. The study is finished and results are being analyzed now.

On Tuesday, the journal Lancet posted an “expression of concern” about a study it published earlier this month of nearly 15,000 COVID-19 patients on the malaria drugs that tied their use to a higher risk of dying in the hospital or developing a heartbeat problem.

Scientists have raised serious questions about the database used for that study, and its authors have launched an independent audit.

That work had a big impact: the World Health Organization suspended use of hydroxychloroquine in a study it is leading, and French officials stopped the drug's use in hospitals. On Wednesday, the WHO said experts who reviewed safety information decided that its study could resume.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.